SGLT2 Inhibitors: A New Class of Diabetes Medications
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of diabetic medications indicated only for the treatment of type 2 diabetes. In conjunction with exercise and a healthy diet, they can improve glycemic control. They have been...
GLP-1 Knowledge Survey Analyses, Complete Series
With this special bonus edition of our highly successful GLP-1 special series, we provide you with an easy list so you can find all of our analyses in one place....
GLP-1 Knowledge Survey, Part VI
This week we finish our analysis of our GLP-1 survey results with a look at prescribing reasons and habits, and how your colleagues decide on GLP-1 analog or DPP-4 inhibitor therapy. Most of the respondents favored Victoza but...
Oxyntomodulin: Partner to GLP-1?
Oxyntomodulin is a gut peptide released in response to a meal. It is synthesized within specialized enteroendocrine cells called L cells. Oxyntomodulin is released from the intestinal L cells 5-10 minutes after ingestion of food in amounts...
GLP-1 Knowledge Survey Part IV
When making a choice amongst GLP-1 Agonists, the number of injections per day and when peak concentrations are reached are both important in selecting therapy. There was almost unanimous consensus that Exenatide is administered twice daily...
GLP-1 Knowledge Survey Part V
Over the past few weeks we have been looking at your colleagues' responses to questions about GLP-1, including mechanisms, interactions, dosing and effectiveness. Over the next two weeks we will examine some of your opinions on starting doses...
ADA: Safety and Efficacy of Once-Monthly Exenatide over 20 Weeks in Patients with Type 2 Diabetes
Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)....
ADA: Linagliptin Has Similar Efficacy to Glimepiride but Improved Cardiovascular Safety over 2 Years in Patients with Type 2 Diabetes Inadequately Controlled on Metformin
Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind...
ADA: Exenatide/Diet vs. Diet Alone for Treatment of Prediabetes
Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes....
Effect of GLP-1 on Cardiovascular Risk Factors
Glucagon-like peptide-1 mimetics improve certain cardiovascular risk factors, although it is unclear if the observed benefits are direct effects or indirect effects due to weight loss....
GLP-1 Knowledge Survey Part III
This week we examine more of your responses regarding GLP-1 therapy....
ADA: Efficacy and Safety of Lixisenatide Once-Daily vs. Exenatide Twice-Daily in Type 2 DM Inadequately Controlled on Metformin (GetGoal-X)
This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients...
GLP-1 Knowledge Survey Part II
We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered....
ADA: CV Risk with Linagliptin in Patients with Type 2 Diabetes: A Pre-Specified, Prospective, and Adjudicated Meta-Analysis from a Large Phase III Program
The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To...
Exenatide Update ADA 71st Scientific Sessions
In order to increase compliance and improve efficacy, there is an experimental long acting exenatide once monthly injectable suspension in the pipeline. This long acting formulation is currently in phase-2 trial and has...
Lixisenatide Update ADA 71st Scientific Sessions
The investigational drug Lyxumia® (lixisenatide), a once daily GLP-1 agonist, is making progress as a newer drug in this increasingly crowded class of drugs. Data from four studies of the GetGoal Phase III clinical...
Liraglutide Update ADA 71st Scientific Sessions
Adding Insulin to Metformin and Liraglutide: A New Sequence of Medication Therapy for Type-2 Diabetes Patients
A new clinical study shows for the first time that the addition of...
GLP-1 Knowledge Survey Part I
Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs...
Disease Progression in Type 2 Diabetes
For the complete article, Disease Progression in Type 2 Diabetes, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk's diabetesinamerica at
The Incretin Effect
For the complete article, The Incretin Effect, and information on other aspects of GLP-1 treatment, please visit Novo Nordisk's diabetesinamerica at
GLP-1 Analogs and DeFronzo's Octet
For nearly 2 decades now, GLP-1 has been heavily investigated as the most promising therapy target in type 2 diabetes patients....
